Aclaris Therapeutics Short Interest Ratio and Short Volume

Short interest is the volume of Aclaris Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 644,000 shares of ACRS short. 1.78% of Aclaris Therapeutics' shares are currently sold short. View details.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.78% of Aclaris Therapeutics' floating shares are currently sold short.

Aclaris Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 644,000 shares, a drop of 15.2% from the previous total of 759,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Aclaris Therapeutics currently has issued a total of 51,804,000 shares. Some of Aclaris Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Aclaris Therapeutics currently has a public float of 36,270,000 shares.

1.78% of Aclaris Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Aclaris Therapeutics: Ionis Pharmaceuticals, Inc. (6.40%), Sarepta Therapeutics, Inc. (0.00%), Allakos Inc. (9.33%), Blueprint Medicines Co. (0.00%), Perrigo Company plc (3.69%), Schrödinger, Inc. (6.64%), Galapagos NV (0.00%), Atea Pharmaceuticals, Inc. (4.89%), Sage Therapeutics, Inc. (0.00%), and Biohaven Pharmaceutical Holding Company Ltd. (0.00%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Aon plc ($5.64 billion), Analog Devices, Inc. ($5.59 billion), Charter Communications, Inc. ($5.47 billion), ViacomCBS Inc. ($4.95 billion), Baidu, Inc. ($3.51 billion), Snap Inc. ($3.18 billion), Airbnb, Inc. ($2.38 billion), The Kroger Co. ($2.28 billion), Expedia Group, Inc. ($2.24 billion), and Bilibili Inc. ($2.06 billion). View all of the most shorted stocks.

Short selling ACRS is an investing strategy that aims to generate trading profit from Aclaris Therapeutics as its price is falling. Aclaris Therapeutics' stock is trading down $0.13 today. To short Aclaris Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Aclaris Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Aclaris Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ACRS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ACRS, twice per month. The most recent reporting period available is March, 15 2021.